1. Nutriband developing Aversa™ Fentanyl, an abuse-deterrent transdermal patch. 2. Illicit fentanyl designated as a weapon of mass destruction by the U.S. government. 3. Aversa™ has potential U.S. sales of $80 to $200 million annually. 4. The technology aims to improve safety and accessibility of fentanyl patches. 5. Nutriband holds patents in 46 countries for its abuse-deterrent technology.
FAQ
Why Bullish?
The development of Aversa™ addresses high demand for safer opioid treatments, which could boost NTRB's sales and market position, as seen with similar pharmaceutical innovations leading to increased stock valuations.
How important is it?
The article highlights a significant product development trajectory that could substantially cash flow to NTRB, making it critically relevant for investor consideration.
Why Long Term?
Successful product rollout and market penetration could enhance sales over several years, similar to other pharma products that gained significant market share after FDA approval.
Nutriband Responds to Executive Order on Fentanyl, Advances Aversa™ Fentanyl Project
Orlando, Fla., December 18, 2025 – Nutriband Inc. (NASDAQ: NTRB), a leader in the development of prescription transdermal pharmaceutical products, has addressed the recent Executive Order issued by the Trump Administration designating illicit fentanyl and its precursor chemicals as weapons of mass destruction. This designation aims to combat the illegal manufacture and distribution of fentanyl, which has overwhelmed the United States.
Understanding Fentanyl in Pain Management
Prescription transdermal fentanyl serves as a crucial treatment option for patients enduring severe, chronic pain who are opioid-tolerant. These patients often find that alternative therapies are insufficient. However, illicit fentanyl poses a significant threat due to its illegal production and trafficking.
Nutriband is at the forefront of addressing this duality through its development of Aversa™ Fentanyl, an innovative abuse-deterrent fentanyl transdermal system, which merges Nutriband’s proprietary Aversa™ technology with Kindeva’s FDA-approved fentanyl patch.
Key Quotes from Nutriband Executives
In a statement regarding the Executive Order, Nutriband emphasized the need to differentiate between illicit fentanyl and FDA-approved prescriptions:
“This designation must not be conflated with FDA-approved prescription fentanyl therapies, which are produced under rigorous regulatory oversight and prescribed to patients suffering from severe chronic pain,” said a company representative. “Access must be maintained for patients needing these critical medications while we combat illicit fentanyl flows.”
Addressing the Epidemic of Fentanyl Abuse
The ongoing epidemic of transdermal fentanyl abuse underscores an urgent need for safer medications. Accidental exposures, particularly among children, have resulted in significant health outcomes, emphasizing the importance of developing abuse-deterrent technologies.
Nutriband's collaboration with Kindeva aims to create a breakthrough with Aversa™ Fentanyl, utilizing a proprietary technology designed to integrate aversive agents into fentanyl patches, significantly reducing risks of misuse and accidental exposure.
Market Potential for Aversa™ Fentanyl
Aversa™ Fentanyl is poised to capture a substantial market share, with projections for annual US sales reaching between $80 million and $200 million. While focusing initially on the US market, Nutriband recognizes the global need for effective pain management and plans to expand its offerings in major medical markets worldwide.
- Development Goal: To make Aversa™ Fentanyl available across all major medical markets.
- Global Intellectual Property: Extensive patent protection in 46 countries, including the US, Europe, Japan, and China.
About Nutriband Inc.
Nutriband Inc. specializes in the development of a diverse range of transdermal pharmaceutical products. Its lead project, Aversa™ Fentanyl, integrates abuse-deterrent technology aimed at enhancing patient safety while ensuring accessibility for legitimate medical use.
For more information, visit www.nutriband.com.